Changes

Jump to navigation Jump to search

CLL Tables: Regions of Recurrent Copy Number Change and CN-LOH (view source)

Revision as of 21:27, 7 November 2020

7,851 bytes added ,  21:27, 7 November 2020
Adding references and gene links
Line 286: Line 286:     
Abbreviations: CNA = copy number aberration; CLL = chronic lymphocytic leukemia; CN-LOH = copy-neutral loss-of-heterozygosity
 
Abbreviations: CNA = copy number aberration; CLL = chronic lymphocytic leukemia; CN-LOH = copy-neutral loss-of-heterozygosity
 +
 +
 +
'''Table 2.  Recurring regions of CN-LOH in CLL'''
 +
{| class="wikitable"
 +
|'''CN-LOH'''
 +
|'''Candidate Gene'''
 +
|'''Association'''
 +
|'''Strength of Evidence for Prognosis (Level*)'''
 +
|'''References'''
 +
|-
 +
|13q
 +
|''miR15a/16-1''
 +
|Biallelic deletion of 13q
 +
|Established (1)
 +
|<ref name=":13">{{Cite journal|last=Hagenkord|first=Jill M.|last2=Monzon|first2=Federico A.|last3=Kash|first3=Shera F.|last4=Lilleberg|first4=Stan|last5=Xie|first5=Qingmei|last6=Kant|first6=Jeffrey A.|date=2010-03|title=Array-based karyotyping for prognostic assessment in chronic lymphocytic leukemia: performance comparison of Affymetrix 10K2.0, 250K Nsp, and SNP6.0 arrays|url=https://pubmed.ncbi.nlm.nih.gov/20075210|journal=The Journal of molecular diagnostics: JMD|volume=12|issue=2|pages=184–196|doi=10.2353/jmoldx.2010.090118|issn=1943-7811|pmc=2871725|pmid=20075210}}</ref><ref>{{Cite journal|last=Pfeifer|first=Dietmar|last2=Pantic|first2=Milena|last3=Skatulla|first3=Ilona|last4=Rawluk|first4=Justyna|last5=Kreutz|first5=Clemens|last6=Martens|first6=Uwe M.|last7=Fisch|first7=Paul|last8=Timmer|first8=Jens|last9=Veelken|first9=Hendrik|date=2007-02-01|title=Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays|url=https://pubmed.ncbi.nlm.nih.gov/17053054|journal=Blood|volume=109|issue=3|pages=1202–1210|doi=10.1182/blood-2006-07-034256|issn=0006-4971|pmid=17053054}}</ref><ref name=":14">{{Cite journal|last=Edelmann|first=Jennifer|last2=Holzmann|first2=Karlheinz|last3=Miller|first3=Florian|last4=Winkler|first4=Dirk|last5=Bühler|first5=Andreas|last6=Zenz|first6=Thorsten|last7=Bullinger|first7=Lars|last8=Kühn|first8=Michael W. M.|last9=Gerhardinger|first9=Andreas|date=2012-12-06|title=High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations|url=https://pubmed.ncbi.nlm.nih.gov/23047824|journal=Blood|volume=120|issue=24|pages=4783–4794|doi=10.1182/blood-2012-04-423517|issn=1528-0020|pmid=23047824}}</ref><ref>{{Cite journal|last=Grygalewicz|first=Beata|last2=Woroniecka|first2=Renata|last3=Rygier|first3=Jolanta|last4=Borkowska|first4=Klaudia|last5=Rzepecka|first5=Iwona|last6=Łukasik|first6=Martyna|last7=Budziłowska|first7=Agnieszka|last8=Rymkiewicz|first8=Grzegorz|last9=Błachnio|first9=Katarzyna|date=2016|title=Monoallelic and biallelic deletions of 13q14 in a group of CLL/SLL patients investigated by CGH Haematological Cancer and SNP array (8x60K)|url=https://pubmed.ncbi.nlm.nih.gov/26740820|journal=Molecular Cytogenetics|volume=9|pages=1|doi=10.1186/s13039-015-0212-x|issn=1755-8166|pmc=4702365|pmid=26740820}}</ref><ref>{{Cite journal|last=Gunnarsson|first=Rebeqa|last2=Mansouri|first2=Larry|last3=Isaksson|first3=Anders|last4=Göransson|first4=Hanna|last5=Cahill|first5=Nicola|last6=Jansson|first6=Mattias|last7=Rasmussen|first7=Markus|last8=Lundin|first8=Jeanette|last9=Norin|first9=Stefan|date=2011-08|title=Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/21546498|journal=Haematologica|volume=96|issue=8|pages=1161–1169|doi=10.3324/haematol.2010.039768|issn=1592-8721|pmc=3148910|pmid=21546498}}</ref><ref name=":15">{{Cite journal|last=Parker|first=H.|last2=Rose-Zerilli|first2=M. J. J.|last3=Parker|first3=A.|last4=Chaplin|first4=T.|last5=Wade|first5=R.|last6=Gardiner|first6=A.|last7=Griffiths|first7=M.|last8=Collins|first8=A.|last9=Young|first9=B. D.|date=2011-03|title=13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/21151023|journal=Leukemia|volume=25|issue=3|pages=489–497|doi=10.1038/leu.2010.288|issn=1476-5551|pmid=21151023}}</ref><ref>{{Cite journal|last=Lehmann|first=Sören|last2=Ogawa|first2=Seishi|last3=Raynaud|first3=Sophie D.|last4=Sanada|first4=Masashi|last5=Nannya|first5=Yasuhito|last6=Ticchioni|first6=Michel|last7=Bastard|first7=Christian|last8=Kawamata|first8=Norihiko|last9=Koeffler|first9=H. Phillip|date=2008-03-15|title=Molecular allelokaryotyping of early-stage, untreated chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/18246537|journal=Cancer|volume=112|issue=6|pages=1296–1305|doi=10.1002/cncr.23270|issn=0008-543X|pmid=18246537}}</ref><ref>{{Cite journal|last=Ouillette|first=Peter|last2=Collins|first2=Roxane|last3=Shakhan|first3=Sajid|last4=Li|first4=Jinghui|last5=Li|first5=Cheng|last6=Shedden|first6=Kerby|last7=Malek|first7=Sami N.|date=2011-11-01|title=The prognostic significance of various 13q14 deletions in chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/21890456|journal=Clinical Cancer Research: An Official Journal of the American Association for Cancer Research|volume=17|issue=21|pages=6778–6790|doi=10.1158/1078-0432.CCR-11-0785|issn=1078-0432|pmc=3207001|pmid=21890456}}</ref>
 +
|-
 +
|17p13
 +
|''[[TP53]]''
 +
|Homozygous ''TP53'' mutations
 +
|Established (1)
 +
|<ref name=":13" /><ref name=":14" /><ref name=":16">{{Cite journal|last=Stevens-Kroef|first=Marian Jpl|last2=van den Berg|first2=Eva|last3=Olde Weghuis|first3=Daniel|last4=Geurts van Kessel|first4=Ad|last5=Pfundt|first5=Rolph|last6=Linssen-Wiersma|first6=Matty|last7=Benjamins|first7=Marloes|last8=Dijkhuizen|first8=Trijnie|last9=Groenen|first9=Patricia Jta|date=2014-01-09|title=Identification of prognostic relevant chromosomal abnormalities in chronic lymphocytic leukemia using microarray-based genomic profiling|url=https://pubmed.ncbi.nlm.nih.gov/24401281|journal=Molecular Cytogenetics|volume=7|issue=1|pages=3|doi=10.1186/1755-8166-7-3|issn=1755-8166|pmc=3905918|pmid=24401281}}</ref><ref name=":15" /><ref>{{Cite journal|last=Saddler|first=Chris|last2=Ouillette|first2=Peter|last3=Kujawski|first3=Lisa|last4=Shangary|first4=Sanjeev|last5=Talpaz|first5=Moshe|last6=Kaminski|first6=Mark|last7=Erba|first7=Harry|last8=Shedden|first8=Kerby|last9=Wang|first9=Shaomeng|date=2008-02-01|title=Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/17971485|journal=Blood|volume=111|issue=3|pages=1584–1593|doi=10.1182/blood-2007-09-112698|issn=0006-4971|pmid=17971485}}</ref>
 +
|-
 +
|11q13-qter
 +
|Includes ''[[ATM]]''
 +
|Monoallelic ''ATM'' deletion
 +
|Suspected (2)
 +
|<ref name=":14" /><ref name=":15" />
 +
|-
 +
|20q11
 +
|Unknown
 +
|None
 +
|N/A (3)
 +
|<ref name=":16" /><ref>{{Cite journal|last=Pei|first=Jianming|last2=Robu|first2=Valentin|last3=Feder|first3=Madelyn|last4=Cheung|first4=Mitchell|last5=Neumann-Domer|first5=Erin|last6=Talarchek|first6=Jacqueline|last7=Dulaimi|first7=Essel|last8=Millenson|first8=Michael M.|last9=Testa|first9=Joseph R.|date=2014-03|title=Copy neutral loss of heterozygosity in 20q in chronic lymphocytic leukemia/small lymphocytic lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/24704113|journal=Cancer Genetics|volume=207|issue=3|pages=98–102|doi=10.1016/j.cancergen.2014.02.005|issn=2210-7762|pmc=4010307|pmid=24704113}}</ref>
 +
|-
 +
|1p36
 +
|Unknown
 +
|None
 +
|N/A (3)
 +
|<ref name=":14" /><ref>{{Cite journal|last=Xu|first=Xinjie|last2=Johnson|first2=Eric B.|last3=Leverton|first3=Lisa|last4=Arthur|first4=Ashley|last5=Watson|first5=Quinn|last6=Chang|first6=Faye L.|last7=Raca|first7=Gordana|last8=Laffin|first8=Jennifer J.|date=2013-09|title=The advantage of using SNP array in clinical testing for hematological malignancies--a comparative study of three genetic testing methods|url=https://pubmed.ncbi.nlm.nih.gov/24269304|journal=Cancer Genetics|volume=206|issue=9-10|pages=317–326|doi=10.1016/j.cancergen.2013.09.001|issn=2210-7762|pmid=24269304}}</ref>
 +
|}
 +
<nowiki>*</nowiki>Level 1: present in WHO classification or professional practice guidelines; Level 2: recurrent in well-powered studies with suspected clinical significance; Level 3: recurrent, but uncertain prognostic significance
    
==Reference==
 
==Reference==
 
<references />
 
<references />
Retrieved from "https://ccga.io/index.php/Special:MobileDiff/9084"

Navigation menu